MRNA Nov 2024 140.000 put
- PR Newswire
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (Nasdaq: MRNA) to include the nomination of two targets for the treatment of autoimmune diseases. Carisma retains all rights in autoimmune disease beyond the two nominated
- Zacks
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
- Investor's Business Daily
Moderna Stock's Three-Year Decline — Is It Time To Sell, Hold Or Buy?
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
